Increased Expression of Tumor-Associated Trypsin Inhibitor, TATI, in Prostate Cancer and in Androgen-Independent 22Rv1 Cells

European Urology

Volumn 52, Issue 6, 2007, Pages 1670-1681

  Paju, Annukka ^a   Hotakainen, Kristina ^a   Cao, Yue ^b   Laurila, Timo ^a   Gadaleanu, Virgil ^c   Hemminki, Akseli ^a,d   Stenman, Ulf Håkan ^a   Bjartell, Anders ^b,e  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Malmö University Hospital   (Sweden)

^d UNIVERSITY OF HELSINKI   (Finland)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

22RV1 cells; Immunohistochemistry; In situ hybridization; Kallikreins; Protease inhibitor

Indexed keywords

ANDROGEN; APROTININ; CHROMOGRANIN A; KI 67 ANTIGEN; MESSENGER RNA; METRIBOLONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BENIGN TUMOR; CANCER CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FLUOROMETRY; GLEASON SCORE; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY;

AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; METRIBOLONE; MIDDLE AGED; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS; TRYPSIN INHIBITOR, KAZAL PANCREATIC;

EID: 35748961384     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.01.096     Document Type: Article

References (30)

1. Paju A., and Stenman U.H. Biochemistry and clinical role of trypsinogens and pancreatic secretory trypsin inhibitor. Crit Rev Clin Lab Sci 43 (2006) 103-142
2. Venesmaa P., Lehtovirta P., Stenman U.H., et al. Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer. Br J Cancer 70 (1994) 1188-1190
3. Venesmaa P., Stenman U.H., Forss M., et al. Pre-operative serum level of tumour-associated trypsin inhibitor and residual tumour size as prognostic indicators in Stage III epithelial ovarian cancer. Brit J Obstet Gynaecol 105 (1998) 508-511
4. Paju A., Jacobsen J., Rasmuson T., et al. Tumor-associated trypsin inhibitor as a prognostic factor in renal cell carcinoma. J Urol 165 (2001) 959-962
5. Kelloniemi E., Rintala E., Finne P., et al., Group F. Tumor-associated trypsin inhibitor (TATI) as a prognostic marker during follow-up of bladder cancer. Urology 62 (2003) 249-253
6. Paju A., Vartiainen J., Haglund C., et al. Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. Clin Cancer Res 10 (2004) 4761-4768
7. Hotakainen K., Bjartell A., Sankila A., et al. Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer. Int J Oncol 28 (2006) 95-101
8. Koivunen E., Itkonen O., Halila H., et al. Cyst fluid of ovarian cancer patients contains high concentrations of trypsinogen-2. Cancer Res 50 (1990) 2375-2378
9. Hirahara F., Miyagi Y., Miyagi E., et al. Trypsinogen expression in human ovarian carcinomas. Int J Cancer 63 (1995) 176-181
10. Yamamoto H., Iku S., Itoh F., et al. Association of trypsin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer 91 (2001) 1324-1331
11. Yamamoto H., Iku S., Adachi Y., et al. Association of trypsin expression with tumour progression and matrilysin expression in human colorectal cancer. J Pathol 199 (2003) 176-184
12. Yamashita K., Mimori K., Inoue H., et al. A tumor-suppressive role for trypsin in human cancer progression. Cancer Res 63 (2003) 6575-6578
13. Wiksten J.P., Lundin J., Nordling S., Kokkola A., Stenman U.H., and Haglund C. High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer. Histopathology 46 (2005) 380-388
14. Paju A., Bjartell A., Zhang W.-M., et al. Expression and characterization of trypsinogen produced in the male genital tract. Am J Pathol 157 (2000) 2011-2021
15. Bjartell A., Paju A., Zhang W.M., et al. Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer. Prostate 64 (2005) 29-39
16. Huhtala M.L. Demonstration of a new acrosin inhibitor in human seminal plasma. Hoppe Seylers Z Physiol Chem 365 (1984) 819-825
17. Osman S., Turpeinen U., Itkonen O., et al. Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidin-biotin system. J Immunol Met 161 (1993) 97-106
18. Lilja H., Christensson A., Dahlen U., et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 37 (1991) 1618-1625
19. Koivunen E., Saksela O., Itkonen O., et al. Human colon carcinoma, fibrosarcoma and leukemia cell lines produce tumor-associated trypsinogen. Int J Cancer 47 (1991) 592-596
20. Yamamoto T., Nakamura Y., Nishide J., et al. Molecular cloning and nucleotide sequence of human pancreatic secretory trypsin inhibitor (PSTI) cDNA. Biochem Biophys Res Commun 132 (1985) 605-612
21. Bjartell A., Björk T., Matikainen M.T., et al. Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium. Urology 42 (1993) 502-510
22. Bjartell A., Malm J., Moller C., et al. Distribution and tissue expression of semenogelin I and II in man as demonstrated by in situ hybridization and immunocytochemistry. J Androl 17 (1996) 17-26
23. Lukkonen A., Sorsa T., Salo T., et al. Down-regulation of trypsinogen-2 expression by chemically modified tetracyclines: association with reduced cancer cell migration. Int J Cancer 86 (2000) 577-581
24. Aihara M., Lebovitz R.M., Wheeler T.M., et al. Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer. J Urol 151 (1994) 1558-1564
25. Jiborn T., Bjartell A., and Abrahamsson P.A. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 51 (1998) 585-589
26. McLoughlin J., Foster C.S., Price P., et al. Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma. Br J Urol 72 (1993) 92-97
27. Sramkoski R.M., Pretlow T.G., Giaconia J.M., et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 35 (1999) 403-409
28. van Bokhoven A., Varella-Garcia M., Korch C., et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 57 (2003) 205-225
29. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 50 (2006) 935-939
30. Morales A. Testosterone and prostate health: debunking myths demands evidence, caution, and good clinical judgment. Eur Urol 50 (2006) 895-897